Long-term major adverse cardiac events (MACE) are reduced in patients with non-flow-limiting vulnerable plaques who undergo preventative percutaneous coronary intervention (PCI) plus optimal medical therapy, compared with only optimal medical therapy, the PREVENT trial shows.